13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
13-valent Pneumococcal Vaccine
Conditions
13-valent Pneumococcal Vaccine, Premature Birth, Immunization, Safety
Trial Timeline
Oct 1, 2010 → Jan 1, 2014
NCT ID
NCT01193335About 13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine is a approved stage product being developed by Pfizer for 13-valent Pneumococcal Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT01193335. Target conditions include 13-valent Pneumococcal Vaccine, Premature Birth, Immunization.
What happened to similar drugs?
0 of 1 similar drugs in 13-valent Pneumococcal Vaccine were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01964716 | Phase 3 | Completed |
| NCT01193335 | Approved | Completed |
| NCT00824850 | Phase 2 | Completed |
Competing Products
1 competing product in 13-valent Pneumococcal Vaccine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| 13-valent pneumococcal conjugate vaccine | Pfizer | Phase 3 | 40 |